LAVIPHARM
Lavipharm Group's consolidated sales increased in the first half of 2024, the company said in a statement, with its consolidated net profit jumping 248.8% compared to the same period last year.
19/09/24 • 19:07
In the first quarter of 2024, Lavipharm Group's total earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 15.9% to €2.85 million from €2.46 million in the same period in 2023.
23/05/24 • 18:11
Commercialization of the product by Lavipharm is expected to take place upon completion of the relevant marketing authorization transfer, during Q2 of 2024
11/12/23 • 12:47